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Epigenetic modification through DNA methylation
is implicated in metabolic disease. Using whole-
genome promoter methylation analysis of skeletal
muscle from normal glucose-tolerant and type 2
diabetic subjects, we identified cytosine hyperme-
thylation of peroxisome proliferator-activated
receptor g (PPARg) coactivator-1 a (PGC-1a) in dia-
betic subjects. Methylation levels were negatively
correlated with PGC-1a mRNA and mitochondrial
DNA (mtDNA). Bisulfite sequencing revealed that
the highest proportion of cytosine methylation within
PGC-1a was found within non-CpG nucleotides.
Non-CpG methylation was acutely increased in
human myotubes by exposure to tumor necrosis
factor-a (TNF-a) or free fatty acids, but not insulin or
glucose. Selective silencing of the DNA methyltrans-
ferase 3B (DNMT3B), but not DNMT1 or DNMT3A,
prevented palmitate-induced non-CpG methylation
of PGC-1a and decreased mtDNA and PGC-1a
mRNA. We provide evidence for PGC-1a hyperme-
thylation, concomitant with reduced mitochondrial
content in type 2 diabetic patients, and link DNMT3B
to the acute fatty-acid-induced non-CpGmethylation
of PGC-1a promoter.
INTRODUCTION
Type 2 diabetes mellitus (T2DM) and its associated metabolic
consequences, such as kidney and heart failure, are leading
causes of morbidity and mortality worldwide. T2DM is a chronic
disorder characterized by insulin resistance in adipose tissue,
liver, and skeletal muscle, which are metabolic organs affected
by an impaired insulin secretion of the b-pancreatic cell. In
particular, defects in skeletal muscle metabolism play a primary
role in the development of whole-body insulin resistance (Eriks-
son et al., 1989), as this tissue is the major site of insulin-medi-
ated glucose disposal (DeFronzo et al., 1985). The mechanisms
underlying insulin resistance and T2DM are incompletely under-Cell Mstood, but genetic and environmental factors such as physical
activity and diet/nutrition are involved.
Epigenetic modifications of the genome, including DNAmeth-
ylation, provide a potential molecular basis for the interaction
between genetic and environmental factors on glucose homeo-
stasis and may contribute to the manifestation of T2DM. Dietary
factors that affect the activity of enzymes supplying methyl
groups can influence the rate of disease manifestation (Van den
Veyver, 2002). Evidence for a nutritional effect on epigenetic
regulation in T2DM is suggested by a generational study in
humans showing that the nutritional status of the parent is closely
linked with an increased risk of T2DM-associated mortality in the
second generation, raising the possibility of a role for epigenetic
modifications of genomic DNA in metabolic disease (Pembrey
et al., 2006). The impact of nutrition on DNA methylation has
been directly shown in the agouti mice, whereby methyl donor
supplementationpreventedDNAhypomethylationof the intracis-
ternal A particle retroviral element into the agouti gene of the
offspring (Cooney et al., 2002; Michaud et al., 1994; Morgan
et al., 1999). Whether epigenetic modifications acutely occur in
somatic tissues of mammalian origin is unknown.
Here, we performed a genome-wide promoter analysis of
DNA methylation to screen for genes differentially methylated in
T2DM. We identified hypermethylation of genes involved in
mitochondrial function, such as the peroxisome proliferator-acti-
vated receptor g (PPARg) coactivator-1 a (PGC-1a), and provide
a mechanism by which elevations in cytokines or lipids induce
non-CpGmethylation of thePGC-1apromoter in skeletalmuscle.
Our results provide insight into the acute reprogramming of gene
expression through methylation in metabolic disease.
RESULTS
Differential Methylation of PGC-1a Promoter in T2DM
We used methylated DNA immunoprecipitation (MeDIP),
combined with microarray technology (Keshet et al., 2006;
Weber et al., 2005), to discover whether changes in DNA meth-
ylation are specific to T2DM. A cohort of normal glucose-tolerant
(NGT) and T2DM male volunteers was studied. The metabolic
characteristics are presented in the Supplemental Data (Table
S1). Importantly, we studied closely age-matched groups to
exclude any possible effect of aging, since aging has beenetabolism 10, 189–198, September 2, 2009 ª2009 Elsevier Inc. 189
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Non-CpG Methylation of PGC-1a Promoter in DiabetesFigure 1. PGC-1a Promoter Is Hypermethylated in T2DM Patients
(A) Genomic localization and representation of the microarray signal using the Integrated Genome Browser for the PGC-1a gene (PPARGC1A). Red bars repre-
sent MeDIP result from patients with normal glucose tolerance (NGT, n = 10) versus with type 2 diabetes (T2DM, n = 10), with a p value < 0.05.
(B) Graphic representation of the bisulfite-sequenced portion on the PGC-1a gene. The transcription start site (arrow) and first exon (black box) are shown. The
CpG sites within the bisulfite-sequenced region are represented (open circles). Expanded Mus musculus, Rattus norvegicus, and Homo sapiens sequence
surrounding the 260 cytosine is shown.
(C) Methylation analysis of the PGC-1a promoter by bisulfite sequencing; percentage of cytosine methylation for unmethylated sequence (UM), in people with
normal glucose tolerance (NGT, n = 7), impaired glucose tolerance (IGT, n = 8), or type 2 diabetes (T2DM, n = 7). Results are mean ± SEM for n = 7 individuals
(*p < 0.05 versus NGT, #p < 0.05 versus UM).
(D) Real-time PCR quantification of PGC-1amRNA expression in vastus lateralis biopsies from NGT (n = 7) or T2DM (n = 7) subjects. Data are normalized to 18S
mRNA and expressed as fold of NGT. Results are mean ± SEM for n = 7 individuals (*p < 0.05).
(E) PGC-1a methylation levels are negatively associated with PGC-1a expression levels. Pearson correlation coefficient (r) and P value are indicated in upper
white box.
(F) Suppression of the Pgc-1a promoter activity by cytosine260methylation. The pCpG vector containing unmethylated (PGC-1a) or in vitro-methylated portion
of PGC-1a promoter (me-260 PGC-1a) was cotransfected with empty pGL4 into 3T3-L1 Adipocytes. Firefly luciferase activity was assayed at 48 hr after trans-
fection and normalized to Renilla luciferase activity. Results are mean ± SEM for three independent experiments (*p < 0.05).associated with methylation events (Bjornsson et al., 2008; Issa
et al., 1994; Siegmund et al., 2007). Oxidative capacity, as
measured by VO2 max, and body mass index (BMI) were not
significantly different between the groups studied. To identify
candidate genes for methylation events, vastus lateralis muscle
biopsies obtained from the volunteers were studied. Samples
enriched for methylated DNA fragments were probed on an array
covering approximately 7.5 kb upstream through 2.45 kb down-
stream of referenced 50 transcription start sites. Of 25,500
promoter regions represented on the array, 838 were differen-
tially methylated (p < 0.05) in skeletal muscle obtained from
NGT versus T2DM subjects. To identify groups of genes with190 Cell Metabolism 10, 189–198, September 2, 2009 ª2009 Elsevisimilar changes in methylation in skeletal muscle from T2DM
patients, we defined the biological processes of the identified
genes using a gene ontology classification (Dennis et al.,
2003). We ranked genes by the level of statistical significance
(p values) and number of genes in the gene ontology clusters
(Table S2). We revealed 44 positive genes as classified in the
mitochondrion ontology (Table S3). Of interest, the PGC-1a
promoter was hypermethylated in skeletal muscle from T2DM
patients compared to NGT subjects (p < 0.05) (Figure 1A).
We validated the MeDIP result for PGC-1a using bisulfite
sequencing. Genomic DNA was extracted from vastus lateralis
muscle biopsies obtained from NGT, impaired glucose-toleranter Inc.
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Non-CpG Methylation of PGC-1a Promoter in DiabetesFigure 2. Methylation Analysis of Genes Flanking PGC-1a by Bisulfite Sequencing
(A) Graphic representation of the genomic localization of the alternative PGC-1a promoter (ALT), DHX15, and GBA3 on chromosome 4. The transcription start site
(arrow), transcribed portion of the genes (black box), and sequenced promoters (red box) are shown. Genomic coordinates are indicated.
(B–D) Percentage of cytosine methylation assessed in skeletal muscle biopsies from NGT or T2DM subjects for GBA3 (B), ALT-PGC-1a (C), and DHX15 (D).
Results are mean ± SEM for n = 8 individuals.
(E–G) Bisulfite sequencing quantification of GBA3 (E), ALT-PGC-1a (F), and DHX15 (G) promoter methylation levels in primary myotubes treated with glucose
(20 mM), insulin (120 nM), palmitate (0.5 mM), oleate (0.5 mM), or TNF-a (1 mM) for 48 hr. Results are mean ± SEM for 30 independent clones.(IGT), or T2DMsubjects (Table S1). Bisulfite sequencingwas per-
formed on a portion of the promoter encompassing337 to37
relative to the +1 transcription start site of PGC-1a gene in each
individual (Figures 1B and S1). The efficiency of the bisulfite
conversion was compared to the unmethylated fragment of the
region of interest of the PGC-1a promoter (Figure 1C). We found
a 2.7- and 2.2-fold increase in unconverted cytosines on the
PGC-1a promoter of IGT and T2DM patients, respectively,
compared to NGT subjects (Figure 1C). An alternative promoter
of human PGC-1a has recently been identified (Yoshioka et al.,
2009). Methylation of a portion encompassing243 to47 rela-
tive to the +1 transcription start site of PGC-1a alternative
promoter was similar in NGT as compared to T2DM subjects.
Through further bisulfite sequencing of DHX15 and GBA3, two
genes proximal to PGC-1a, we reveal that hypermethylation in
T2DM is not broadly altered on a wide portion of the chromatin,
but is specific to the canonical PGC-1a promoter (Figure 2).
Most of the methylated cytosines were found within non-CpG
dinucleotides (Figure S1). Of interest, the hypermethylation
pattern observed in the T2DM patients was unrelated to family
history of the disease. Our findings highlight the potential physio-Cell Mlogical importance of non-CpG methylation in human skeletal
muscle, since non-CpGmethylation has been almost exclusively
reported in plants and embryonic stem cells (Grandjean et al.,
2007; Meyer et al., 1994; Ramsahoye et al., 2000).
PGC-1a Methylation Controls PGC-1a Expression
Given that DNA methylation located within or close to the 50
region of genes has been associated with regulation of gene
expression (Costello andPlass, 2001),wenext assessedwhether
PGC-1a mRNA expression was altered in skeletal muscle biop-
sies from NGT and T2DM subjects. PGC-1a mRNA content
was decreased 38% in T2DMpatients (Figure 1D) and negatively
correlated with promoter methylation (r = 0.56, p = 0.036)
(Figure 1E). Further investigation of the role of PGC-1a promoter
methylation ongene activity using a gene reporter assay revealed
that in vitromethylation of a single cytosine residue (located260
relative to the +1 transcription start site) caused amarked reduc-
tion of gene activity (Figure 1F). Several lines of evidence suggest
that insulin resistance and T2DM are associated with decreased
skeletalmusclemitochondrial function,which can reduce cellular
andwhole-body oxidative capacity (Kelley et al., 2002; Simoneauetabolism 10, 189–198, September 2, 2009 ª2009 Elsevier Inc. 191
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Non-CpG Methylation of PGC-1a Promoter in Diabetesand Kelley, 1997). Reductions in mitochondrial density have also
been proposed as a primary cause of mitochondrial dysfunction
in insulin-resistant states (Boushel et al., 2007). Here, we show
that PGC-1a promoter methylation was negatively correlated
with mitochondrial DNA (mtDNA) content, as measured by ratio
of mtDNA to nuclear DNA (nDNA) using real-time quantitative
PCR (r = 0.55, p = 0.043) (Figure S2).
Decreased Mitochondrial Content in Patients
with T2DM
PGC-1a is a key factor that coordinately regulates the expres-
sion of a subset of mitochondrial genes and participates in the
overall mitochondrial function in the cell (Lin et al., 2005). To
examine whether mitochondrial content is altered in skeletal
muscle from T2DM patients, proteins from the mitochondrial
respiratory chain were measured in crude lysates. The relative
amounts of succinate-ubiquinol reductase (SUO or complex
II), core I (complex III), and cytochrome C (CytC) were signifi-
cantly decreased in T2DM patients compared with NGT
subjects (Figures 3A and 3B). Additionally, the level of expres-
sion of the mitochondrial transcription factor A (TFAM), a key
protein in the regulation of mtDNA quantity, was significantly
decreased in T2DM compared with NGT subjects (Figures 3A
and 3B). The ratio of mtDNA per nucleus was decreased 22%
in T2DM patients (Figure 3C). Ultrastructural analysis of skeletal
muscle obtained from each cohort further supports these find-
ings, as both mitochondrial number and area were significantly
Figure 3. Decreased Mitochondrial Markers in Type 2 Dia-
betic Patients
(A) Expression of mitochondrial proteins. Western blot analysis of indi-
vidual content of TFAM, core I (or complex III), succinate-ubiquinol
reductase (SUO or complex II), and cytochrome C (CytC) is shown.
(B) Quantification of western blot was normalized by GAPDH expres-
sion in NGT (n = 7, open box) and T2DM (n = 7, black box) subjects.
Results are mean ± SEM (*p < 0.05, **p < 0.005).
(C) Decreased mtDNA content in T2DM patients. Quantification of
mtDNA to nDNA ratio using real-time PCR in NGT (n = 8, open box)
and T2DM (n = 8, black box). Results are mean ± SEM (*p < 0.05).
reduced (p < 0.001) in T2DM patients compared with
NGT subjects (Figures 4A–4C). Thus, mitochondrial
markers were decreased in skeletal muscle from T2DM
patients, indicative of altered mitochondrial content in
this cohort.
Role of Free Fatty Acids and TNF-a in PGC-1a
Methylation
Alterations in the extracellular milieu, including hypergly-
cemia, hyperinsulinemia, elevated free fatty acids, and
elevated cytokines, can cause peripheral insulin resis-
tance in T2DM. To investigate whether these external
factors directly and acutely alter the methylation status,
we used primary human skeletal muscle cells derived
from vastus lateralis biopsies obtained from NGT men
and screened for putative factors involved in PGC-1a
methylation. Primary human skeletal muscle cultures
were incubated for 48 hr with various factors known to
induce insulin resistance (Figure 5A). TNF-a, palmitate,
and oleate induced hypermethylation of the PGC-1a promoter,
whereas high glucose or insulin concentrations were without
effect. Similar to our results inmuscle tissue, bisulfite sequencing
revealed that the majority of the methylated cytosines were
located outside of CpG nucleotides (Figure 5B). We next
evaluated whether these changes occurred as a consequence
of whole-genome methylation using luminometric methylation
assays (LUMA). Upon palmitate treatment, we found that both
global CpA and CpT methylation within 50-CCA/TGG-30 was
increased from 1.6% to 4.2% (Figure 6A), although CpG methyl-
ationwithin the 50-CCGG-30 sequencewas unaltered (Figure 6B).
In vastus lateralis, we observed similar CpG and non-CpG levels
(Figures 6C and 6D). These results provide further evidence of
high non-CpG methylation in human skeletal muscle. Moreover,
global methylation levels were unchanged in T2DM patients
(Figures 6C and 6D), suggesting that hypermethylation is gene
specific. Collectively, these data provide evidence that free fatty
acids acutely induce non-CpG methylation at the PGC-1a
promoter and at the whole-genome level in primary human
myocytes.
DNMT3B Is Involved in Palmitate-Induced DNA
Methylation in Human Muscle Cells
In mammals, three functional DNA methyltransferase (DNMT)
isoforms have been identified: DNMT1, DNMT3A, and DNMT3B.
To identify whether DNMTs are involved in palmitate-induced
PGC-1a promoter methylation, we selectively silenced DNMT1,192 Cell Metabolism 10, 189–198, September 2, 2009 ª2009 Elsevier Inc.
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Non-CpG Methylation of PGC-1a Promoter in DiabetesDNMT3A, and DNMT3B in human primary muscle cells. Gene
silencing of either DNMT1 or DNMT3A failed to rescue palmi-
tate-induced downregulation of PGC-1a mRNA and mitochon-
drial gene expression (Figure S3). In contrast, silencing of
DNMT3B 43% (Figure 7A) prevented palmitate-induced PGC-
1a promoter methylation (Figure 7B). Furthermore, the palmi-
tate-induced reduction of mtDNA content, as evaluated by the
mtDNA to nDNA ratio, was partly prevented by DNMT3B
silencing (Figure 7C). Quantitative PCR was also performed to
detect any variation in the expression of genes related to
mitochondrial function and biogenesis (Figure 7D). DNMT3B
silencing prevented the palmitate-induced downregulated
mRNA expression of PGC-1a, TFAM, citrate synthase (CS), and
carnitine palmitoyltransferase (CPT)-2. Conversely, the effect of
palmitate treatment to upregulate mRNA expression of CPT-1
and CytC was unaltered by DNMT3B silencing. Nuclear respira-
tory factor 1 (NRF-1) was unaltered by either palmitate treatment
or DNMT3B silencing. Thus, the expression of a subset of
genes important for mitochondrial regulation is downregulated
following palmitate exposure in a DNMT3B-dependent manner.
We cannot directly link PGC-1a to the regulation of these genes,
because changes in gene expression could have been caused by
a direct effect of palmitate. These genes may themselves be
targets of dynamic regulation via methylation, or they may be
regulated as a consequence of the reduction in PGC-1a expres-
sion. For example, ourMeDIP analysis revealedTFAMandCPT-2
are hypermethylated in skeletalmuscle fromT2DMpatients (data
not shown). These results provide evidence that DNMT3B plays
a role in palmitate-induced DNA methylation and the control
of mitochondrial marker gene expression in human skeletal
muscle cells. However, protein content of DNMT isoforms were
unchanged following 48 hr exposure of human myocytes to
high concentrations of glucose, insulin, palmitate, oleate, or
TNF-a (Figure S4A). In skeletal muscle from NGT and T2DM
subjects, quantitative analysis of DNMT isoforms using RT-PCR
revealedmRNAexpression ofDNMT3B (normalized to actin) was
increased in T2DM versus NGT subjects (378 ± 42 versus 215 ±
46 arbitrary units, respectively; p < 0.05). In contrast, mRNA
expression of DNMT1 (1685 ± 201 versus 1580 ± 315 arbitrary
units) andDNMT3A (6168±633 versus 6161±857 arbitrary units)
was unchanged between T2DMandNGT subjects, which further
supports a role of DNMT3B in increased methylation levels.
However, protein content was unaltered between T2DM and
NGTsubjects (FigureS4B). Thus, collectively, our results suggest
that enzymatic activation of DNMT3B, rather than changes
in protein expression, is involved in hypermethylation of the
PGC-1a promoter.
Figure 4. Decreased Mitochondrial Content in Type 2 Diabetic
Patients
(A–C) Mitochondrial ultrastructure was examined in skeletal muscle from NGT
(n = 3) and T2DM (n = 3) subjects by transmission electron microscopy. Repre-
sentative images of samples from an NGT subject and a T2DM patient are
shown (A). Note the mitochondria located between contractile units (arrows).
Images are of type I fibers (note the thick Z-line); scale bar represents 500 nm.
The number (B) and area (C) of mitochondria were determined from images
captured at 28003 with an area of 7.2 mm2. Bars represent the mean of all
images counted, and points represent means of individual subjects. Area
data are expressed in mitochondria area per total image area (*p < 0.001).
Figure 5. Free Fatty Acids Induce PGC-1a Promoter Methylation in
Primary Human Myocytes
(A) Bisulfite sequencing quantification of PGC-1a promoter methylation levels
in cells treated with insulin (120 nM), glucose (20 mM), TNF-a (1 mM), palmitate
(0.5 mM), or oleate (0.5 mM) for 48 hr. Results are mean ± SEM for 30 indepen-
dent clones (*p < 0.05 versus basal).
(B) Visualization of bisulfite sequencing results as analyzed by MethTools 2.0
(Grunau et al., 2000) (http://genome.imb-jena.de/methtools/) in basal condi-
tions (upper panel) or after 48 hr of palmitate treatment (lower panel).Cell Metabolism 10, 189–198, September 2, 2009 ª2009 Elsevier Inc. 193
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Mitochondrial dysfunction has been proposed to contribute to
impaired fat oxidation and excess lipid storage in skeletal muscle
(Morino et al., 2006). Here, we provide evidence for epigenetic
modifications on the PGC-1a promoter in skeletal muscle from
T2DM patients using genome-wide promoter screening of DNA
methylation. PGC-1a is a master regulator of mitochondrial
biogenesis and function (Wu et al., 1999). Hypermethylation of
the PGC-1a promoter was associated with reduced PGC-1a
expression and implicates a mechanism for decreased mito-
chondrial content in T2DM.
Downregulation of PGC-1a expression in T2DM subjects
was previously reported (Mootha et al., 2003). Consistent
with the notion that mitochondrial oxidative capacity is
impaired in T2DM, we report that PGC-1a and several mito-
chondrial markers, including TFAM, CytC, SUO, and core I,
as well as mtDNA/nDNA and mitochondrial size and number,
are reduced. In the present study, we couple PGC-1a promoter
hypermethylation with reduced mitochondrial density and
provide a potential mechanism for mitochondrial dysfunction
in T2DM. Whether alterations in mitochondrial function or
PGC-1a levels are directly linked to insulin resistance or dia-
betes remains unclear. However, we observed a negative asso-
ciation between PGC-1a promoter methylation and mRNA
levels and also provide evidence that DNA methylation influ-
ences PGC-1a promoter activity. Furthermore, the PGC-1a
promoter is hypermethylated in skeletal muscle from IGT
subjects, indicating this may be an early event in the pathogen-
esis of insulin resistance in T2DM. Nevertheless, reduced skel-
etal muscle PGC-1a mRNA expression has been noted in some
(Patti et al., 2003), but not all (Karlsson et al., 2006), nondia-
betic family history-positive subjects, despite impairments in
mitochondrial function (Morino et al., 2005). Thus, additional
factors may also contribute to the reduced mitochondrial
content in history-positive nondiabetic subjects and T2DM
Figure 6. Luminometric Assay Analysis of Global
DNA Methylation
(A–D) Global CpG and non-CpG methylation analysis in
primary human myocytes exposed to palmitate is shown
in (A) and (B). Global CpG and non-CpG methylation anal-
yses in vastus lateralis biopsies from people with NGT or
T2DM are shown in (C) and (D). Genomic DNA was
digested using the restriction enzymes Psp6I and AjnI.
The ratio (Psp6I)/(AjnI) was plotted to a standard curve to
determine the percent CCWGG methylation levels.
Results are mean ± SEM (A and C). Genomic DNA was
also digested using the restriction enzymes MspI, HpaII,
and EcoRI. The value [1  (HpaII/EcoRI)/(MspI/EcoRI)] 3
100 was used as percent CCGGmethylation level. Results
are mean ± SEM (B and D).
patients. Indeed, changes in PGC-1a mRNA
expression and mitochondrial function may
be related to alterations in physical activity or
nutritional status between the NGT and T2DM
subjects, rather than diabetes per se. Whether
methylation of the PGC-1a promoter is an early
pathogenic event in the pathogenesis of insulin
resistance in T2DM or a more generalized consequence
causally related to features of IGT and T2DM requires further
evaluation.
Lipid overload can impair skeletal muscle oxidative capacity
and increase intramuscular triglyceride content, thereby
providing a role for nutritional factors in the development of
peripheral insulin resistance in T2DM (Borkman et al., 1993;
Dobbins et al., 2001; Valtuen˜a et al., 1997). The hypermethylation
of thePGC-1apromoter upon free fatty acid exposure is compat-
ible with previous evidence of a close relationship betweenPGC-
1a mRNA levels in cultured myotubes and circulating fatty acid
levels of the donor and strongly implicates fatty acids in the
epigenetic modification of PGC-1a mRNA expression (Staiger
et al., 2006). We also observed PGC-1a promoter hypermethyla-
tion upon TNF-a exposure. Excessive levels of free fatty acids
and TNF-a stimulate the accumulation of the sphingolipid ceram-
ide and various ceramide metabolites (Summers and Nelson,
2005), which potentially forms a link between free fatty acid and
TNF-a-induced DNA methylation.
Several lines of evidence support a role for epigenetic
processes in the regulation of metabolic disease, indicating
a strong link between gene and environment. Changes in DNA
methylation levels are associated with alterations in the expres-
sion of genes involved in mitochondrial function, including cyto-
chrome c oxidase subunit VIIa polypeptide 1 (COX7A1), NADH
dehydrogenase (ubiquinone) 1 beta subcomplex 6 (NDUFB6),
and PGC-1a in humans (Ling et al., 2007, 2008; Ro¨nn et al.,
2008). Moreover, the lysine (K)-specific demethylase 3A
(Kdm3a) has been implicated in the transcriptional regulation of
PPARa (Tateishi et al., 2009). From our MeDIP screen of skeletal
muscle biopsies, we retrieved numerous genes with differential
methylation status in skeletal muscle from T2DM versus NGT
volunteers, including subsets of genes involved in primary meta-
bolic processes and mitochondrial function. Future efforts in
systems biology will be required to understand the complexity
of gene-environment interactions in health and disease. DNA194 Cell Metabolism 10, 189–198, September 2, 2009 ª2009 Elsevier Inc.
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Non-CpG Methylation of PGC-1a Promoter in DiabetesFigure 7. DNMT3B Is Involved in the Palmitate-Induced Decrease of mtDNA
(A) Specific siRNA-mediated depletion of DNMT3B protein was confirmed relative to the scrambled siRNA by western blot analysis 48 hr after transfection of
siRNA. Pan-actin was used as a loading control. A representative image is shown.
(B–D) Analysis in cells transfected with the scrambled siRNA (SCR) after palmitate treatment in primary human myocytes previously transfected with the scram-
bled siRNA (SCR + PALM) or theDNMT3B siRNA (siRNADNMT3B + PALM). DNMT3B silencing prevents palmitate-induced PGC-1amethylation (B). Methylation
analysis of the PGC-1a promoter is performed by bisulfite sequencing. Results are mean ± SEM for ten independent clones and for three different subjects
(*p < 0.05 versus scr.). DNMT3B silencing partially reverses the palmitate-induced decrease inmtDNA content (C). The nDNA versusmtDNA ratio was determined
in primary human myocytes using quantitative PCR. Results are mean ± SEM for three different subjects (*p < 0.05 versus scramble; #p < 0.05 versus scramble +
palmitate). Relative expression of genes in mitochondrial function after DNMT3B silencing is shown in (D). Quantitative PCR was used to determine the mRNA
levels of PGC-1a, TFAM, CS, CPT-1, CPT-2, CytC, and NRF-1. Results are mean ± SEM for three different subjects (*p < 0.05 versus scramble; #p < 0.05 versus
scramble + palmitate).methylation may provide a mechanism to link environmental
factors with the long-term establishment of T2DM.
Rapid changes in the DNA methylation pattern occur during
early mammalian development or during cell division (Adams,
1971; Li, 2002). Here, we show that DNA methylation can be
acutely induced in somatic cells. PGC-1a promoter hypermethy-
lation in response to TNF-a or free fatty acids occurred in a time-
dependent manner (data not shown), indicating dynamic DNA
hypermethylation occurs in differentiated, nondividing cells.
Discovery of whether DNA methylation changes are involved in
the adaptation to the extracellular environment requires further
investigation. However, the absence of an association between
PGC-1a methylation levels and family history of diabetes in our
study provides evidence that PGC-1a hypermethylation in
T2DMmay occur as a consequence of the deleterious metabolic
milieu directly on somatic cells, rather than through inherited
factors.
DNA methylation in mammals is predominantly reported on
cytosines of the dinucleotide sequence CpG. However, non-
CpG methylation was described at measurable levels in embry-
onic stem cells (Grandjean et al., 2007; Ramsahoye et al.,
2000). Using various approaches, we provide evidence that
non-CpG methylation is readily observed in human skeletal
muscle. Of interest, we observed greater non-CpG methylationCell Melevels on PGC-1a and TFAM (data not shown) promoters
compared to global levels. Although further investigations are
necessary to determine if non-CpGmethylation is more concen-
trated to promoter regionswithin thegenome, our finding that 7%
of cytosines within the sequence CCAGG or CCTGG are methyl-
ated in human skeletal muscle suggests that further attention
should be given to non-CpG methylation when using current
DNA methylation analysis techniques. We identified PGC-1a by
MeDIP. Given that the PGC-1a promoter contains a higher
proportion of non-CpG sites (4 CpG and 56 non-CpG within the
region analyzed), non-CpG methylation is likely to contribute to
a greater extent in PGC-1a promoter precipitation. This raises
the importance of considering non-CpG methylation when inter-
preting MeDIP analysis.
Here, we highlight that changes in the metabolic environment
lead to a rapid epigenetic modulation of PGC-1a, which has
been implicated in the development of T2DM and related meta-
bolic disorders. T2DM remains a complex and multifaceted
disease, the exact cause of which has yet to be resolved. While
obesity and genetic predisposition can contribute to the devel-
opment of T2DM, diet and physical activity can also have a posi-
tive impact on insulin sensitivity. Epigenetic modifications
provide a mechanism by which external environmental factors
can modify genetic predisposition for health and disease.tabolism 10, 189–198, September 2, 2009 ª2009 Elsevier Inc. 195
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Reagents, Tissue Preparation, and Cell Culture
The following antibodies were used for the western blot analysis: mtTFA (A-17)
and GAPDH (FL-335) were purchased from Santa Cruz Biotechnology, Inc.
(Santa Cruz, CA); SUO and core I (16D10) were purchased from Molecular
Probes Invitrogen AB, Sweden; CytC was from BD Biosciences, Inc. (Franklin
Lakes, NJ). The DNMT1 antibody was obtained from Abcam (Cambridge, UK);
DNMT3A and DNMT3B antibodies were obtained from Cell Signaling Tech-
nology (Danvers, MA). Sodium betabisulfite, hydroquinone, TNF-a, oleate
and palmitate were purchased from Sigma-Aldrich (Stockholm).
Study Participants
Experiments were performed with approval from the local ethics committee.
All studies were performed according to the Declaration of Helsinki. Informed
written consent was obtained from all participants before testing was initiated.
Clinical characteristics of NGT (n = 17), IGT (n = 8), and T2DM (n = 17) partic-
ipants are presented (Table S1). T2DM patients were treated with diet, sulfo-
nylureas, or metformin. Individuals taking b-adrenergic receptor blockers,
ACE inhibitors, or hormonal therapy were excluded from the study.
Clinical Analysis
Serum insulin levelwasmeasuredwith a commercially available fluoroimmuno-
assay (Delphia; Perkin Elmer; Waltham, MA). Plasma glucose was measured
using a glucose oxidase method (Beckman Coulter; Fullerton, CA), and
HbA1c was assessed by HPLC using an autoanalyzer (RG41 5RA; Menarini
Diagnostics; Berkshire, UK). Plasma triacylglycerol wasmeasured using enzy-
matic methods (Roche Diagnostics; Basel, Switzerland). Peak pulmonary
oxygen uptake rate (VO2 peak) was determined by an incremental exercise
test to volitional fatigue on an electromagnetically braked cycle ergometer
(SensorMedics; Yorba Linda, CA). Expired oxygen and carbon dioxide content
was measured with oxygen and carbon dioxide analyzers, respectively. Venti-
lationwasmeasuredby a turbine flow transducer. Peak VO2was considered as
the highest VO2 attained during the latter stages of the test.
Skeletal Muscle Biopsy
Skeletal muscle biopsies (50–100 mg) were obtained under local anesthesia
(Lidokain hydrochloride 5 mg/ml) from the vastus lateralis portion of the quad-
riceps femoris using aWeils-Blakesly contochome. Biopsy samples formRNA,
DNA, and protein analysis were immediately frozen and stored in liquid
nitrogen until analysis. For ultrastructural examination, skeletal muscle bio-
psies from a subgroup of the NGT and T2DM cohort (NGT, n = 3; T2DM,
n = 3) were fixed in 3% glutaraldehyde plus 300 mM sucrose in 0.1 M cacody-
late buffer (pH 7.4) overnight, postfixed for 1 hr in 1% osmium tetroxide, dehy-
drated through a graded alcohol series, and embedded in Durcupan resin
(Sigma). Ultrathin 70 nm sections were placed on copper mesh grids (Electron
Microscopy Science; Hatfield, PA), counterstained with 2% uranyl acetate and
lead citrate, and examined with a Morgagni 268 transmission electron micro-
scope. Ten random images were captured using the AMT camera system
(Advanced Microscopy Techniques; Danvers, MA) at 28003. Total mitochon-
drial number and volume density were determined for each image.
Human Skeletal Muscle Cell Culture
Vastus lateralis muscle biopsies were collected in cold phosphate-buffered
saline (PBS) supplemented with 1% PeSt (100 U ml1 penicillin/100 mg ml1
streptomycin). Biopsies were dissected free from visible connective and fat
tissue, minced finely, mixed with trypsin-EDTA, and incubated with gentle
agitation at 37C for 5 min. Thereafter, undigested tissue was allowed to settle,
and the supernatant containing liberated satellite cellswascollected andmixed
with growthmedia (DMEM/Ham’s F12 supplementedwith 20%FBS, 1%PeSt,
1% Fungizone). The remaining tissue was repeatedly digested for another 10
and 15 min. The collected cell suspension was incubated in a noncoated Petri
dish for 1 hr to selectively promote adherence of nonmyogenic cells. The super-
natant was thereafter transferred to culture flasks, and subcultures 4–5 were
used for experiments. At 80% confluence, myotube formation was initiated
by lowering serum levels to 2%for 6days.During the last 48hr of differentiation,
cells were treated with factors known to induce insulin resistance, 120 nM
insulin, 20 mM glucose, 1 mM TNF-a, 0.5 mM palmitate, or 0.5 mM oleate.196 Cell Metabolism 10, 189–198, September 2, 2009 ª2009 ElsevieOn the second day of myotube differentiation, siRNAs (80 pmol) were trans-
fected using Lipofectamine 2000 (Invitrogen) in serum and antibiotic-free
DMEM. After overnight incubation, cells were washed and put back on differ-
entiation media. Control cultures were transfected with a scrambled siRNA
construct encoding a nonspecific siRNA without mammalian homology. The
siRNAduplexeswere obtained fromSigmaGenosys (Sigma-Aldrich, Sweden).
The sense sequences were the following: 50-[dT]GGAAUGGCAGAUGCCAA
CAGC[dT]-30, 50-[dT]GAAAGCCAAGGUCAUUGCA[dT]-30, 50-[dT]GCUACAC
ACAGGACUUGAC[dT]-30 for DNMT1, DNMT3A, and DNMT3B, respectively.
MeDIP Assay
PurifiedgenomicDNAwasprepared fromculturedcells and tissue samplesand
digested overnight with AluI restriction enzyme (New England Biolabs; Ipswich,
MA) to obtain fragments of 256 base pairs on average. We used 4 mg digested
DNA for a standard MeDIP assay, as described (Weber et al., 2005). Denatu-
ratedDNAwas immunoprecipitatedusing10mgofmonoclonal antibodyagainst
5-methylcytidine (Eurogentec; Seraing, Belgium) in 300 ml IP buffer (10 mM
sodium phosphate [pH 7.0], 140 mM NaCl, 0.05% Triton X-100) for 5 hr at
4C and washed three times with 800 ml IP buffer. Immunoprecipitated DNA
was recovered with Proteinase K digestion followed by column-based purifica-
tion (DNAWizard; Promega; Madison, WI), amplified and hybridized on human
tiling array 1.0R chip according to Affymetrix Chromatin Immunoprecipitation
Assay protocol (Santa Clara, CA). DNA immunoprecipitates were fragmented
and labeled according to recommended protocols (http://www.affymetrix.
com/Auth/support/downloads/manuals/chromatin_immun_ChIP.pdf) at the
Bioinformatics and Expression Analysis Core Facility, Karolinska Institutet.
Hybridization to theGeneChip Human Promoter 1.0R Array as well as scanning
of the arrays was performed according to standard Affymetrix protocols.
Analysis of Tiling Array Data
Arrays were quantile-normalized within treatment/control replicate groups and
scaled to have a median feature intensity of 130. Using Tiling Array Analysis
(TAS version 1.0.15, Affymetrix) software, biological replicates were verified
tobe very similar to eachother and formed relatively tight clusterswhenplotting
log average intensity versus log difference in intensity between the two dupli-
cates (MvA Plot). Probe-level intensities from each group were summarized
with TAS by using the ‘‘two-sample comparison analysis’’ option and band-
width 130. Differentiallymethylated regionswere calledby applying a threshold
of p < 0.05 and by combining neighboring methylated probes allowing
a maximal gap of 100 bases and requiring a minimal run of 70 bases. Analysis
of bed files generated by interval analysis was performed using the integrated
genome browser (IGB, Affymetrix). Genes were considered as ‘‘positives’’
when positive array signals were displayed in a region between 7 kb upstream
and 3 kb downstream of the +1 transcription start site. In the case of two genes
closely neighboring the hit, the gene closer to the hit was taken into account.
Nucleic Acid Purification and Real-Time PCR
DNA from 10–20 mg of vastus lateralis muscle was extracted using DNeasy
Blood & Tissue columns (QIAGEN). The total amount of DNA recovered was
determined by spectrophotometry. For RNA extraction, 10 mg of skeletal
muscle tissue was homogenized in 1 ml of TRIzol reagent (Sigma), and RNA
was purified according to recommendations of the manufacturer. The RNAs
from cultured cells were also purified using TRIzol reagent. One microgram
of purified RNA was then treated with DNase I using a DNA-free kit (Ambion)
according to the manufacturer’s protocol. DNase-treated RNA was used as
a template for cDNA synthesis using the SuperScript First-Strand Synthesis
System (Invitrogen) with random hexamers. cDNA quantity was measured
using real-time PCR with the ABI PRISM 7000 sequence detector system
and fluorescence-based SYBRGreen technology (Applied Biosystems; Foster
City, CA). PCR was performed in a final volume of 25 ml, consisting of diluted
cDNA sample, 13 SYBR Green PCR Master Mix (Applied Biosystems),
primers optimized for each target gene, and nuclease-free water. All samples
were analyzed in duplicates. Primers were designed using Primer Express
computer software (Applied Biosystems).
Bisulfite Sequencing
Bisulfite treatment was performed as described (Olek et al., 1996), with the
following adaptations: briefly, 1 mg of genomic DNA was embedded in a 2%r Inc.
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prepared bisulfite solution (4M sodiumbetabisulfite, Sigma; 250mMhydroqui-
none, Sigma [pH 5.0]) was added to each reaction tube containing one single
bead. The reaction mixtures were incubated for 4 hr at 50C under exclusion
of light. Treatment was stopped by equilibrations against 1 ml of Tris-EDTA
(TE) (4 3 15 min) followed by desulphonation in 500 ml of 0.2 M NaOH (2 3
15 min). The reaction was neutralized, and beads were washed with 1 ml TE
(2 3 15 min). Prior to PCR, beads were equilibrated against 1 ml of ddH2O
(2 3 30 min). For amplification of the region from 337 to 37 of PGC-1a
promoter, the following primers were used: sense 50 TAT AGT TAT TTT GTT
ATG AAA TAG GGA GTT TT G 30; antisense 50 CCA ATC ACA TAA CAA AAC
TAT TAA AAA ATA A 30. For amplification of the region from 243 to 47 of
the alternative PGC-1a promoter, the following primers were used: sense 50
ATA GGG TTG TTG GAA AGT ATA TGA TAT T 30; antisense 50 AAA AAA CAC
TCA CAA CAA AAA CTT C 30. For DHX15: sense 50 TGG AGG TAG TTT TGG
TTG TTA TTA T 30; antisense 50 CAT TTT AAA ACA AAT AAT TTC TTT TT 30.
For GBA3: sense 50 AAA TGG TTA AAA GTG GTT ATT TTT ATA GAG 30; anti-
sense 50 CAA AAC ACC CAT TTA CCT AAT ATT TTA C 30. The obtained PCR
fragments were purified from an agarose gel using MinElute Gel Extraction Kit
(QIAGEN) and cloned into pDrive vector using PCR Cloning Kit (QIAGEN),
according themanufacturer’s protocol. Individual cloneswere grown and plas-
mids purified using QIAprep Spin Miniprep Kit (QIAGEN). For each condition,
10–50 clones were sequenced using T7 promoter primer on an ABI 3730xl
DNA Analyzer platform at Cogenics (Hope End, UK).
MtDNA Content
The ratio of mitochondrial versus nuclear DNA was determined as described
(Walker et al., 2005), with the following adaptations: briefly, 10 ml of purified
DNA at 1 ng/ml was amplified in a 25 ml PCR reaction containing 13 SYBR
GreenMasterMix (Applied Biosystems) and 100 nMof each primer. The ampli-
fication was monitored in real-time using the ABI Prism 7000 Real-Time PCR
machine (Applied Biosystems). The primers were designed to target nDNA
(forward: CTT GCA GTG AGC CGA GAT T A; reverse: GAG ACG GAG TCT
CGC TCT GTC) or mtDNA (forward: AAT ATT AAA CAC AAA CTA CCA CCT
ACC T; reverse: TGG TTC TCA GGG TTT GTT ATA A).
Western Blot Analysis
Muscle tissue biopsies were freeze-dried and dissected free from blood and
connective tissue. Muscles were homogenized in buffer containing 50 mM
HEPES (pH 7.6), 150 mM NaCl, 1% Triton X-100, 1 mM Na3VO4, 10 mM NaF,
30 mM Na4P2O7, 10% (v/v) glycerol, 1 mM benzamidine, 1 mM dithiothreitol,
10 mg/ml leupeptin, 1 mM PMSF, and 1 mM microcystin. Protein was deter-
mined by the BCA (bicinchoninic acid) protein assays kit from Pierce (Thermo
Fisher Scientific;Waltham,MA). Sampleswere resuspended in Laemmli buffer,
and proteins were separated on 12%SDS-PAGE. Proteins were transferred to
polyvinylidenedifluoride membranes (Millipore; Billerica, MA) and subjected to
western blot analysis. After incubationwith primary antibody,membraneswere
washed and incubated with secondary antibody linked to horseradish peroxi-
dase (Bio-Rad; Hercules, CA). Multiple film exposures were used to ensure
that proteins were detected in linear range of protein band saturation. Results
were quantified by densitometry using Gel Doc 1000 imaging system with
Molecular Analyst software, version 1.5 (Bio-Rad Laboratories).
LUMA
For LUMA interrogation of CpG methylation within the CCGG sequence,
experimental conditions were as previously described (Karimi et al., 2006).
Restriction enzymes (HpaII, MspI, and EcoRI) and Tango buffer (33 mM Tris-
acetate [pH 7.9], 10 mM Mg-acetate, 66 mM K-acetate, 0.1 mg/ml BSA) were
purchased from Fermentas (Stockholm). The PSQ 96 SNP reagents for pyro-
sequencing were purchased from Biotage (Uppsala). Briefly, 500–1000 ng
of genomicDNAwas submitted to a double digestion using either HpaII + EcoRI
or MspI + EcoRI in Tango buffer (4 hr at 37C). Following digestion, pyro-
sequencing annealing buffer was added to each reaction, transferred to 96-well
pyrosequencing plates, and analyzed using a pyrosequencer machine with an
assay sequence defined as AC/TCGA. Percent CCGG methylation levels were
calculated with the following equation: [1 (HpaII/EcoRI)/(MspI/EcoRI)]3 100.
For LUMA interrogation of CpA or CpT methylation within the CCA/TGG
sequence, the restriction enzymes used were Psp6I and AjnI from SibEnzymeCell MLtd. (Novosibirsk, Russia). Extracted DNA was digested using Psp6I or AjnI in
Buffer Y (33 mM Tris-acetate [pH 7.9], 10 mM magnesium acetate, 66 mM
potassium acetate, 1 mM DTT) purchased from SibEnzyme. Following diges-
tion, pyrosequencing annealing buffer was added to each reaction, transferred
to 96-well pyrosequencing plates, and analyzed using a pyrosequencer
machine with an assay sequence defined as AC/TCGA. The ratio (Psp6I)/
(AjnI) was plotted to a standard curve in order to determine the percent
CCWGG methylation levels.
Statistics
Correlations were calculated using Pearson’s coefficient with the SigmaStat
2.03 software (Access Softek; Berkeley, CA). Results are presented as mean
± SEM. Differences between groups were determined by two-tailed unpaired
Student’s t test. P < 0.05 was considered significant.
ACCESSION NUMBERS
MeDIP array results have been archived at EMBL-EBI (http://www.ebi.ac.uk) in
a publicly accessible database (MIAMExpress; accession number E-MEXP-
2253).
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